Harbin Medisan Pharmaceutical Co Ltd (002900) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.008x

Based on the latest financial reports, Harbin Medisan Pharmaceutical Co Ltd (002900) has a cash flow conversion efficiency ratio of -0.008x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-15.53 Million ≈ $-2.27 Million USD) by net assets (CN¥1.90 Billion ≈ $278.76 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Harbin Medisan Pharmaceutical Co Ltd balance sheet quality to measure how much of total assets are equity-financed.

Harbin Medisan Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)

This chart illustrates how Harbin Medisan Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Harbin Medisan Pharmaceutical Co Ltd's earnings quality to evaluate the quality of earnings relative to operating cash generation.

Harbin Medisan Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Harbin Medisan Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
CoinShares PLC Ordinary Shares NASDAQ:CSHR	-0.001x
Third Coast Bancshares, Inc. NASDAQ:TCBX	0.040x
Beijing Changjiu Logistics Ltd SHG:603569	-0.013x
Shanghai Metersbonwe Fashion&Accessories Co Ltd SHE:002269	-0.519x
Hume Industries Berhad KLSE:5000	0.240x
Beijing Tianyishangjia New Material Corp Ltd SHG:688033	-0.043x
JL MAG RARE-EARTH H YC1 F:3KLA	N/A
Invesco Quality Municipal Income Closed Fund NYSE:IQI	0.018x

Annual Cash Flow Conversion Efficiency for Harbin Medisan Pharmaceutical Co Ltd (2012–2024)

The table below shows the annual cash flow conversion efficiency of Harbin Medisan Pharmaceutical Co Ltd from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Harbin Medisan Pharmaceutical Co Ltd.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥2.16 Billion ≈ $316.68 Million	CN¥30.69 Million ≈ $4.49 Million	0.014x	-14.66%
2023-12-31	CN¥2.15 Billion ≈ $314.35 Million	CN¥35.69 Million ≈ $5.22 Million	0.017x	-76.43%
2022-12-31	CN¥2.05 Billion ≈ $300.27 Million	CN¥144.64 Million ≈ $21.17 Million	0.070x	+1290.28%
2021-12-31	CN¥2.12 Billion ≈ $309.71 Million	CN¥-12.53 Million ≈ $-1.83 Million	-0.006x	-135.40%
2020-12-31	CN¥1.79 Billion ≈ $262.16 Million	CN¥-4.51 Million ≈ $-659.52K	-0.003x	-101.46%
2019-12-31	CN¥1.85 Billion ≈ $270.96 Million	CN¥320.14 Million ≈ $46.85 Million	0.173x	+16.45%
2018-12-31	CN¥1.97 Billion ≈ $288.24 Million	CN¥292.46 Million ≈ $42.80 Million	0.148x	+21.92%
2017-12-31	CN¥1.83 Billion ≈ $268.51 Million	CN¥223.46 Million ≈ $32.70 Million	0.122x	-57.43%
2016-12-31	CN¥808.17 Million ≈ $118.26 Million	CN¥231.18 Million ≈ $33.83 Million	0.286x	+3.68%
2015-12-31	CN¥727.97 Million ≈ $106.53 Million	CN¥200.85 Million ≈ $29.39 Million	0.276x	+44.50%
2014-12-31	CN¥609.16 Million ≈ $89.14 Million	CN¥116.31 Million ≈ $17.02 Million	0.191x	-58.28%
2013-12-31	CN¥365.13 Million ≈ $53.43 Million	CN¥167.10 Million ≈ $24.45 Million	0.458x	+27.29%
2012-12-31	CN¥342.72 Million ≈ $50.15 Million	CN¥123.22 Million ≈ $18.03 Million	0.360x	--

About Harbin Medisan Pharmaceutical Co Ltd

SHE:002900 China Drug Manufacturers - Specialty & Generic

Market Cap

$521.72 Million

CN¥3.57 Billion CNY

Market Cap Rank

#11863 Global

#3362 in China

Share Price

CN¥11.27

Change (1 day)

-1.66%

52-Week Range

CN¥9.18 - CN¥15.90

All Time High

CN¥32.63